Mankind Pharma Q1FY27 Revenue up 13% to ₹4,031 Cr; PAT grows 29% to ₹574 Cr
Mankind Pharma reported Q1 FY27 consolidated revenue of ₹4,031 Cr, up 12.9% YoY. EBITDA grew 24.7% to ₹1,060 Cr, and PAT increased 29.1% to ₹574 Cr. Domestic revenue rose 10.5% to ₹3,426 Cr, while exports grew 29.0% to ₹605 Cr. An earnings concall is scheduled for July 30, 2026.
The announcement details significant financial results for the quarter, including revenue and profit growth, which are key metrics for investors and will likely impact the company's stock performance.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with margin improvements, indicating positive financial performance.
Mankind Pharma announced its financial results for the first quarter ended June 30, 2026, reporting a consolidated revenue from operations of ₹4,031 Crore, an increase of 12.9% year-on-year.
The company's EBITDA grew by 24.7% to ₹1,060 Crore, with EBITDA margin improving by 250 basis points to 26.3%. Profit After Tax (PAT) rose by 29.1% to ₹574 Crore, and PAT margin improved by 170 basis points to 14.2%.
Domestic revenue increased by 10.5% to ₹3,426 Crore, driven by an 11.0% growth in the domestic business (excluding Consumer Health) to ₹3,180 Crore. Exports contributed ₹605 Crore, showing a significant growth of 29.0% year-on-year.
The Vice Chairman & Managing Director, Mr. Rajeev Juneja, highlighted the revenue growth of approximately 13% and EBITDA margin improvement to 26.3%. The domestic business (excluding Consumer Health) grew by 11.0%, with notable performance in chronic segments (cardiac and anti-diabetes) and strong growth in the BSV specialty business. The OTC segment grew by approximately 4%, and the international business saw a 29% increase.
In the Consumer Healthcare segment, revenue grew by 4% year-on-year, with market share gains in key brands like Manforce, Preganews, and Gas-o-fast. The Exports segment registered healthy growth of 29% year-on-year, with Mankind launching 1 new product in the US in Q1FY27.
The company will be holding an earnings concall on July 30, 2026, from 06:30 pm to 07:30 pm IST.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.